VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
2.1000
-0.0100 (-0.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.1100
Open2.1500
Bid2.00 x 1100
Ask2.82 x 3200
Day's Range2.0700 - 2.1500
52 Week Range1.4400 - 4.0000
Volume37,321
Avg. Volume85,726
Market Cap74.204M
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.61
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    New Research Coverage Highlights Kandi Technologies Group, AquaVenture, Bridgeline Digital, VolitionRX, USD Partners LP, and ZK International Group Co. — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswirelast month

    VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, Nov. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended September 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, November 8, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with good progress being made on many fronts demonstrating the diverse nature of our platform technology.

  • PR Newswire2 months ago

    VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Thursday, November 8, 2018 at 8:30 am Eastern time ISNES, Belgium , Oct. 31, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a ...

  • PR Newswire2 months ago

    VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics

    ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mission at Texas A&M University. The meeting was sponsored in part by the Wallonia Export-Investment Agency (AWEX), a long-time supporter of Volition in Belgium. Volition will now test its Nu.Q™ platform in larger trials in veterinary medicine. Volition's extensive intellectual property portfolio includes coverage of veterinary medicine applications.

  • PR Newswire3 months ago

    VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board

    ISNES, Belgium , Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video ...

  • PR Newswire3 months ago

    VolitionRx Limited to Attend Multiple Conferences in September

    ISNES, Belgium , Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds and/or its Executive Vice President of Investor ...

  • Zacks Small Cap Research4 months ago

    VNRX: More Compelling Prostate Cancer Data, Opportunities Remain for Near-Term Data-Driven Value Inflection

    VolitionRx (VNRX) reported Q2 financial results and provided a business update. Despite the significant operational progress, including that related to their numerous (and growing number of) trials in various cancers, operating spend through the first six months of 2018 was up just $2.4M (+35%) from the prior year period, to $9.2M. For some context of the efficiency of VNRX’s product development, we estimate their average cost per sample (of all ongoing trials) is approximately $100 – a small fraction of the estimated ~$3.5k per sample cost of pivotal studies of other non-invasive CRC diagnostics.

  • ACCESSWIRE4 months ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Volitionrx Limited (NYSE MKT: VNRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...

  • Associated Press4 months ago

    VolitionRX: 2Q Earnings Snapshot

    The Singapore-based company said it had a loss of 15 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.91. A year ago, they were trading at $2.92. _____ This story ...

  • PR Newswire4 months ago

    VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 14, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with strong progress being made on many fronts.

  • PR Newswire4 months ago

    Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. At 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). "This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer.

  • PR Newswire4 months ago

    VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

    ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology for the diagnosis of endometriosis through a simple blood test. Volition has now commenced running its discovery grade assays through the cohorts and expects to report preliminary data over the coming months. Dr. Jake Micallef, Volition's Chief Scientific Officer, commented "Endometriosis is a potentially debilitating inflammatory condition in which the endometrial tissue that normally lines the inside of the uterus, grows outside the uterus, typically damaging the ovaries, fallopian tubes or other tissues of the pelvic cavity.

  • PR Newswire4 months ago

    VolitionRx Announces $9 Million Private Placement

    ISNES, Belgium, Aug. 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a price of $1.80 per share, as well as a warrant to purchase up to an additional 5 million shares of Volition common stock at an exercise price of $3.00 per share payable in cash, which will result in gross proceeds to Volition before the deduction of estimated offering expenses of $9 million (excluding the proceeds from any exercise of the warrant). The warrant will have a term of one year from the closing date and be exercisable for a period of 6 months, commencing on the 6-month anniversary of the closing date. The private placement is expected to close on or about August 10, 2018, subject to customary closing conditions.

  • PR Newswire4 months ago

    VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Tuesday, August 14, 2018 at 8:30 am Eastern time ISNES, Belgium , Aug. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...

  • VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
    PR Newswire5 months ago

    VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today

    ISNES, Belgium, Aug. 1, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner (https://www.activemotif.com/catalog/1266/NuQ-total-assay). This kit, based on Volition's proprietary Nucleosomics® technology, is the first in a range of kits due to be released over the coming months. Founder and Chairman of Active Motif, Joseph M. Fernandez, commented "We are continuously looking for innovative products in the field of epigenetics and believe that Nucleosomics® is a breakthrough technology. These RUO kits will provide researchers throughout the world with a new way to explore epigenetic modifications in circulating cell-free nucleosomes across different diseases from clinical samples.

  • PR Newswire5 months ago

    Volition Extends Global Reach of its Clinical Trial Program

    ISNES, Belgium , July 10 , 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its already impressive clinical trial program with the ...

  • PR Newswire5 months ago

    Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region

    ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding of approximately $700,000 from the Walloon Regional Government. Including this latest amount, Volition has received approximately $3.7 million in non-dilutive funding from a number of local agencies to date. Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, "We are grateful to the Walloon Region, and in particular to the Vice-President of the Walloon Government and Minister for Economy, Industry, Research, Innovation, Digital, Employment and Training, Mr. Pierre-Yves Jeholet for his continued support of the Company.

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on VolitionRX Ltd. (VNRX) with a Target Price of $7.00

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Volition RX Ltd. with a Target Price of $7.00. VolitionRX Ltd. (NYSE American: VNRX) is a life sciences company focused on developing simple, easy-to-use blood-based tests to accurately diagnose a broad range of cancers and other conditions. VNRX's novel Nu.Q® family of blood-based diagnostics tests are based on the company's proprietary Nucleosomics® technology platform, which identifies and measures nucleosomes in the bloodstream.

  • Zacks Small Cap Research7 months ago

    VNRX: Triage Data Expected in Coming Weeks, Frontline By Year-End

    VolitionRx (VNRX) reported Q1 financial results and provided a business update. Initial studies could start in Asia prior to current year-end and if all goes to plan, initial commercial introduction could happen sometime next year.

  • PR Newswire7 months ago

    VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018

    ISNES, Belgium , May 14, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference ...

  • Associated Press7 months ago

    VolitionRX: 1Q Earnings Snapshot

    The Singapore-based company said it had a loss of 17 cents per share. In the final minutes of trading on Thursday, the company's shares hit $2.24. A year ago, they were trading at $3.58. _____ This story ...

  • PR Newswire7 months ago

    VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results.

  • PR Newswire7 months ago

    VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

    ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® technology. Founder and Chairman of Active Motif, Joseph M. Fernandez commented "We are continuously looking for innovative products in the field of epigenetics and believe Nucleosomics® is a breakthrough technology. The RUO kits are based on the same Nu.Q™ immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.

  • PR Newswire7 months ago

    VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium , May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it ...

  • VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check
    Simply Wall St.9 months ago

    VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check

    VolitionRx Limited (AMEX:VNRX) is a small-cap stock with a market capitalization of US$71.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...